TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.

Samuel R. Denmeade,Hao Wang,Neeraj Agarwal,David C. Smith,Michael T. Schweizer,Mark N. Stein,Vasileios J. Assikis,Przemyslaw Twardowski,Thomas W. Flaig,Russell Z. Szmulewitz,Jeffrey M. Holzbeierlein,Ralph J. Hauke,Guru Sonpavde,Jorge A. Garcia,Arif Hussain,Oliver Sartor,Shifeng Mao,Harry Cao,Wei Fu,Ting Wang,Rehab Abdallah,Su Jin Lim,Vanessa Bolejack,Channing J. Paller,Michael A. Carducci,Mark C. Markowski,Mario A. Eisenberger,Emmanuel S. Antonarakis

TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.

2021

PURPOSEProstate cancer (PCa) becomes resistant to androgen ablation through adaptive upregulation of the androgen receptor in response to the low-testosterone microenvironment. Bipolar androgen the...

Keywords:

Downregulation and upregulation
Oncology
Androgen receptor
Prostate cancer
Androgen Therapy
Cancer
Androgen
Internal medicine
Asymptomatic
Enzalutamide
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations